Physician profile
Ryan Lok
NPI 1851771786
$4,973.79
in general payments reported to CMS, 2019-2025
31 companies · $34.95 in 2025
The $34.95 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $1,897 · 2023: $1,565 · 2024: $1,199 · 2025: $34.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,699.35 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $748.13 | 2021-2024 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.52 | 2021-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $426.16 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $384.09 | 2022-2024 | Acthar |
| Glaxosmithkline, LLC. | $348.60 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Ethicon INC. | $298.19 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $257.45 | 2022-2024 | Dupixent |
| Inari Medical, INC. | $252.16 | 2022 | |
| Mylan Specialty L.P. | $239.83 | 2022-2024 | Yupelri |
| Genentech USA, INC. | $200.81 | 2021-2023 | Xolair |
| Grifols USA, LLC | $185.09 | 2021-2024 | Prolastin-C Liquid, Xembify |
| United Therapeutics Corporation | $180.26 | 2022-2024 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $135.84 | 2023-2024 | Glassia, Cuvitru |
| Amgen INC. | $101.21 | 2022-2024 | Tezspire |
| Vapotherm INC | $101.01 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $87.12 | 2022-2023 | Ruconest |
| Ani Pharmaceuticals, INC. | $80.34 | 2024 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $64.79 | 2022-2024 | Opsumit, Uptravi |
| Insmed, INC. | $52.60 | 2022 | |
| Harmony Biosciences LLC | $52.50 | 2022 | |
| Astellas Pharma US INC | $24.62 | 2023 | Cresemba |
| Baxter Healthcare | $24.41 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Intuitive Surgical, INC. | $21.80 | 2022 | |
| Csl Behring | $19.71 | 2022 | |
| Emd Serono, INC. | $18.52 | 2022 | |
| Hospira, INC. | $18.34 | 2023 | |
| Pulmonx Corporation | $18.19 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Pfizer INC. | $16.45 | 2024 | |
| Electromed, INC. | $16.27 | 2022 | |
| Boston Scientific Corporation | $13.17 | 2022 | |
| Philips North America LLC | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.